Convalescent Plasma for the Treatment of COVID-19 : Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Annals of internal medicine - 174(2021), 1 vom: 01. Jan., Seite 93-95 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pau, Alice K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.01.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7326/M20-6448 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315468041 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315468041 | ||
| 003 | DE-627 | ||
| 005 | 20231225154959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7326/M20-6448 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315468041 | ||
| 035 | |a (NLM)32976026 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pau, Alice K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convalescent Plasma for the Treatment of COVID-19 |b Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 700 | 1 | |a Aberg, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Belperio, Pamela S |e verfasserin |4 aut | |
| 700 | 1 | |a Coopersmith, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Crew, Page |e verfasserin |4 aut | |
| 700 | 1 | |a Grund, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Gulick, Roy M |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Carly |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, H Clifford |e verfasserin |4 aut | |
| 700 | 1 | |a Masur, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Kanal |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdany, Jinoos |e verfasserin |4 aut | |
| 700 | 1 | |a Tebas, Pablo |e verfasserin |4 aut | |
| 700 | 0 | |a National Institutes of Health COVID-19 Treatment Guidelines Panel |e verfasserin |4 aut | |
| 700 | 1 | |a Gulick, Roy M |e investigator |4 oth | |
| 700 | 1 | |a Lane, H Clifford |e investigator |4 oth | |
| 700 | 1 | |a Masur, Henry |e investigator |4 oth | |
| 700 | 1 | |a Pau, Alice K |e investigator |4 oth | |
| 700 | 1 | |a Aberg, Judith |e investigator |4 oth | |
| 700 | 1 | |a Adimora, Adaora |e investigator |4 oth | |
| 700 | 1 | |a Baker, Jason |e investigator |4 oth | |
| 700 | 1 | |a Kreuzige, Lisa Baumann |e investigator |4 oth | |
| 700 | 1 | |a Bedimo, Roger |e investigator |4 oth | |
| 700 | 1 | |a Belperio, Pamela S |e investigator |4 oth | |
| 700 | 1 | |a Cantrill, Stephen V |e investigator |4 oth | |
| 700 | 1 | |a Collier, Ann C |e investigator |4 oth | |
| 700 | 1 | |a Coopersmith, Craig |e investigator |4 oth | |
| 700 | 1 | |a Daar, Eric |e investigator |4 oth | |
| 700 | 1 | |a Davis, Susan L |e investigator |4 oth | |
| 700 | 1 | |a Dzierba, Amy L |e investigator |4 oth | |
| 700 | 1 | |a Evans, Laura |e investigator |4 oth | |
| 700 | 1 | |a Gallagher, John J |e investigator |4 oth | |
| 700 | 1 | |a Gandhi, Rajesh |e investigator |4 oth | |
| 700 | 1 | |a Glidden, David V |e investigator |4 oth | |
| 700 | 1 | |a Grund, Birgit |e investigator |4 oth | |
| 700 | 1 | |a Hardy, Erica J |e investigator |4 oth | |
| 700 | 1 | |a Hinkson, Carl |e investigator |4 oth | |
| 700 | 1 | |a Hughes, Brenna L |e investigator |4 oth | |
| 700 | 1 | |a Johnson, Steven |e investigator |4 oth | |
| 700 | 1 | |a Keller, Marla J |e investigator |4 oth | |
| 700 | 1 | |a Kim, Arthur |e investigator |4 oth | |
| 700 | 1 | |a Lennox, Jeffrey L |e investigator |4 oth | |
| 700 | 1 | |a Levy, Mitchell M |e investigator |4 oth | |
| 700 | 1 | |a Martin, Gregory |e investigator |4 oth | |
| 700 | 1 | |a Naggie, Susanna |e investigator |4 oth | |
| 700 | 1 | |a Pavia, Andrew T |e investigator |4 oth | |
| 700 | 1 | |a Seam, Nitin |e investigator |4 oth | |
| 700 | 1 | |a Simpson, Steven Q |e investigator |4 oth | |
| 700 | 1 | |a Swindells, Susan |e investigator |4 oth | |
| 700 | 1 | |a Tebas, Pablo |e investigator |4 oth | |
| 700 | 1 | |a Tien, Phyllis |e investigator |4 oth | |
| 700 | 1 | |a Waghmare, Alpana A |e investigator |4 oth | |
| 700 | 1 | |a Wilson, Kevin C |e investigator |4 oth | |
| 700 | 1 | |a Yazdany, Jinoos |e investigator |4 oth | |
| 700 | 1 | |a Campbell, Danielle M |e investigator |4 oth | |
| 700 | 1 | |a Harrison, Carly |e investigator |4 oth | |
| 700 | 1 | |a Burgess, Timothy |e investigator |4 oth | |
| 700 | 1 | |a Francis, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Sheikh, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Uyeki, Timothy M |e investigator |4 oth | |
| 700 | 1 | |a Walke, Robert |e investigator |4 oth | |
| 700 | 1 | |a Nason, Martha C |e investigator |4 oth | |
| 700 | 1 | |a Singh, Kanal |e investigator |4 oth | |
| 700 | 1 | |a Crew, Page |e investigator |4 oth | |
| 700 | 1 | |a Kuriakose, Safia |e investigator |4 oth | |
| 700 | 1 | |a Lerner, Andrea M |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of internal medicine |d 1945 |g 174(2021), 1 vom: 01. Jan., Seite 93-95 |w (DE-627)NLM000012777 |x 1539-3704 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:93-95 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7326/M20-6448 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2021 |e 1 |b 01 |c 01 |h 93-95 | ||